Zacks Company Profile for Precigen, Inc. (PGEN : NSDQ) |
|
|
|
Company Description |
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.
Number of Employees: 191 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $1.28 |
Daily Weekly Monthly
 |
20 Day Moving Average: 1,048,413 shares |
Shares Outstanding: 207.69 (millions) |
Market Capitalization: $265.85 (millions) |
Beta: 2.43 |
52 Week High: $8.72 |
52 Week Low: $1.12 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-21.95% |
-14.48% |
12 Week |
-37.26% |
-31.92% |
Year To Date |
-65.50% |
-58.97% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Helen Sabzevari - Chief Executive Officer
Randal J. Kirk - Chairman
Harry Thomasian Jr. - Chief Financial Officer
Cesar L. Alvarez - Director
Steven Frank - Director
|
|
Peer Information
Precigen, Inc. (CORR.)
Precigen, Inc. (RSPI)
Precigen, Inc. (CGXP)
Precigen, Inc. (BGEN)
Precigen, Inc. (GTBP)
Precigen, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74017N105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
|
|
Share - Related Items
Shares Outstanding: 207.69
Most Recent Split Date: (:1)
Beta: 2.43
Market Capitalization: $265.85 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $0.00 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-0.37 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/08/22 |
|
|
|
|